Regulation mechanism of microRNAs in non-small cell lung cancer

Current Pharmaceutical Design

Volumn 23, Issue 39, 2017, Pages 5973-5982

  Gong, Feng Yun ^a   Bai, Tao ^a   Zhang, Ding Yu ^a   Huang, Chao Lin ^a   Lv, Jing ^a   Wang, Jing Li ^a   Hu, Xu Dong ^a   Wang, Juan ^a   Liu, Wei ^a  

^a The Medical Treatment Center of Wuhan   (China)

Author keywords

MicroRNAs; Non coding RNAs; Non small cell lung cancer (NSCLC); Oncogenes; Regulation mechanism; Tumor

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TRANSCRIPTION FACTOR ZEB1; ZINC FINGER E BOX BINDING HOMEOBOX 2; ANTINEOPLASTIC AGENT; MICRORNA;

BIOLOGICAL ACTIVITY; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION REGULATION; GENE REPRESSION; GENE TARGETING; GENETIC REGULATION; HISTONE ACETYLATION; HISTONE METHYLATION; HUMAN; NON SMALL CELL LUNG CANCER; ONCOGENE; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; RNA DEGRADATION; RNA GENE; RNA PROCESSING; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; TUMOR-RELATED GENE; ANIMAL; DRUG EFFECT; DRUG RESISTANCE; GENETICS; LUNG TUMOR; METABOLISM;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MICRORNAS;

EID: 85043337861     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612823666170714153424     Document Type: Review

References (219)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65(1): 5-29.
2. Torre LA, Siegel RL, Jemal A. Lung cancer statistics. Adv Exp Med Biol 2016; 893: 1-19.
3. Rosell R, Cuello M, Cecere F, et al. Treatment of non-small-cell lung cancer and pharmacogenomics: Where we are and where we are going. Curr Opin Oncol 2006; 18(2): 135-43.
4. Pirker R. Milestones in the systemic treatment of lung cancer. Memo 2017; 10(1): 22-6.
5. Skouras VS, Maragkos C, Grapsa D, Syrigos KN. Targeting neovasculature with multitargeted antiangiogenesis tyrosine kinase inhibitors in non-small cell lung cancer. BioDrugs 2016; 30(5): 421-39.
6. Chu BF, Otterson GA. Incorporation of antiangiogenic therapy into the non-small-cell lung cancer paradigm. Clin Lung Cancer 2016; 17(6): 493-506.
7. Passiglia F, Listì A, Castiglia M, et al. EGFR inhibition in NSCLC: New findings…. and opened questions? Crit Rev Oncol Hematol 2017; 112: 126-35.
8. Liu TC, Jin X, Wang Y, Wang K. Role of epidermal growth factor receptor in lung cancer and targeted therapies. Am J Cancer Res 2017; 7(2): 187-202.
9. Drizou M, Kotteas EA, Syrigos N. Treating patients with ALK-rearranged non-small-cell lung cancer: Mechanisms of resistance and strategies to overcome it. Clin Transl Oncol 2017; 19(6): 658-66.
10. Cheema PK, Menjak IB, Winterton-Perks Z, et al. Impact of Reflex EGFR/ ALK testing on time to treatment of patients with advanced nonsquamous non-small-cell lung cancer. J Oncol Pract 2016; JOP2016014019.
11. Tan WL, Jain A, Takano A, et al. Novel therapeutic targets on the horizon for lung cancer. Lancet Oncol 2016; 17(8): e347-62.
12. Melosky B. Current treatment algorithms for patients with metastatic non-small cell, non-squamous lung cancer. Front Oncol 2017; 7: 38.
13. Kim ES. Chemotherapy resistance in lung cancer. Adv Exp Med Biol 2016; 893: 189-209.
14. Falcone E, Grandoni L, Garibaldi F, et al. Infinity: An in-silico tool for genome-wide prediction of specific DNA matrices in miRNA genomic loci. PLoS One 2016; 11(4): e0153658.
15. Cai Y, Yu X, Hu S, Yu J. A brief review on the mechanisms of miRNA regulation. Genomics Proteomics Bioinformatics 2009; 7(4): 147-54.
16. Adams L, Non-coding RN. Non-coding RNA: Pri-miRNA processing: Structure is key. Nat Rev Genet 2017; 18(3): 145.
17. Fiannaca A, Rosa M, Paglia L, Rizzo R, Urso A. MiRNATIP: a SOM-based miRNA-target interactions predictor. BMC Bioinformatics 2016; 17(Suppl. 11): 321.
18. Reyes-Herrera PH, Ficarra E, Acquaviva A, Macii E. miREE: miRNA recognition elements ensemble. BMC Bioinformatics 2011; 12: 454.
19. Toscano-Garibay JD, Aquino-Jarquin G. Transcriptional regulation mechanism mediated by miRNA-DNA•DNA triplex structure stabilized by Argonaute. Biochim Biophys Acta 2014; 1839(11): 1079-83.
20. Chekulaeva M, Filipowicz W. Mechanisms of miRNA-mediated post-transcriptional regulation in animal cells. Curr Opin Cell Biol 2009; 21(3): 452-60.
21. Rhoads RE. miRNA regulation of the translational machinery. Preface. Prog Mol Subcell Biol 2010; 50: v-vi.
22. Liang G, Weisenberger DJ. DNA methylation aberrancies as a guide for surveillance and treatment of human cancers. Epigenetics 2017; 12(6): 416-32.
23. Brueckner B, Stresemann C, Kuner R, et al. The human let-7a-3 locus contains an epigenetically regulated microRNA gene with oncogenic function. Cancer Res 2007; 67(4): 1419-23.
24. Cui R, Meng W, Sun HL, et al. MicroRNA-224 promotes tumor progression in nonsmall cell lung cancer. Proc Natl Acad Sci USA 2015; 112(31): E4288-97.
25. Welch C, Chen Y, Stallings RL. MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene 2007; 26(34): 5017-22.
26. He L, He X, Lim LP, et al. A microRNA component of the p53 tumour suppressor network. Nature 2007; 447(7148): 1130-4.
27. Bommer GT, Gerin I, Feng Y, et al. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol 2007; 17(15): 1298-307.
28. Lodygin D, Tarasov V, Epanchintsev A, et al. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 2008; 7(16): 2591-600.
29. Kitano K, Watanabe K, Emoto N, et al. CpG island methylation of microRNAs is associated with tumor size and recurrence of non-small-cell lung cancer. Cancer Sci 2011; 102(12): 2126-31.
30. Donzelli S, Mori F, Bellissimo T, et al. Epigenetic silencing of miR-145-5p contributes to brain metastasis. Oncotarget 2015; 6(34): 35183-201.
31. Zhan M, Wen F, Liu L, Chen Z, Wei H, Zhou H. JMJD1A promotes tumorigenesis and forms a feedback loop with EZH2/let-7c in NSCLC cells. Tumour Biol 2016; 37(8): 11237-47.
32. Xu C, Zhang L, Duan L, Lu C. MicroRNA-3196 is inhibited by H2AX phosphorylation and attenuates lung cancer cell apoptosis by downregulating PUMA. Oncotarget 2016; 7(47): 77764-76.
33. Tange S, Oktyabri D, Terashima M, Ishimura A, Suzuki T. JARID2 is involved in transforming growth factor-beta-induced epithelial-mesenchymal transition of lung and colon cancer cell lines. PLoS One 2014; 9(12): e115684.
34. Pang AL, Title AC, Rennert OM. Modulation of microRNA expression in human lung cancer cells by the G9a histone methyltransferase inhibitor BIX01294. Oncol Lett 2014; 7(6): 1819-25.
35. Pandey M, Sahay S, Tiwari P, Upadhyay DS, Sultana S, Gupta KP. Involvement of EZH2, SUV39H1, G9a and associated molecules in pathogenesis of urethane induced mouse lung tumors: Potential targets for cancer control. Toxicol Appl Pharmacol 2014; 280(2): 296-304.
36. Chen DQ, Huang JY, Feng B, et al. Histone deacetylase 1/Sp1/microRNA-200b signaling accounts for maintenance of cancer stem-like cells in human lung adenocarcinoma. PLoS One 2014; 9(10): e109578.
37. Shen Z, Chen L, Yang X, et al. Downregulation of Ezh2 methyltransferase by FOXP3: New insight of FOXP3 into chromatin remodeling? Biochim Biophys Acta 2013; 1833(10): 2190-200.
38. Watanabe K, Amano Y, Ishikawa R, et al. Histone methylation-mediated silencing of miR-139 enhances invasion of non-small-cell lung cancer. Cancer Med 2015; 4(10): 1573-82.
39. Incoronato M, Urso L, Portela A, et al. Epigenetic regulation of miR-212 expression in lung cancer. PLoS One 2011; 6(11): e27722.
40. Chen CQ, Chen CS, Chen JJ, et al. Histone deacetylases inhibitor trichostatin A increases the expression of Dleu2/miR-15a/16-1 via HDAC3 in non-small cell lung cancer. Mol Cell Biochem 2013; 383(1-2): 137-48.
41. Adams CM, Eischen CM. Histone deacetylase inhibition reveals a tumor-suppressive function of MYC-regulated miRNA in breast and lung carcinoma. Cell Death Differ 2016; 23(8): 1312-21.
42. Jeon HS, Lee SY, Lee EJ, et al. Combining microRNA-449a/b with a HDAC inhibitor has a synergistic effect on growth arrest in lung cancer. Lung Cancer 2012; 76(2): 171-6.
43. Shen Y, Pan X, Zhao H. The histone demethylase PHF8 is an oncogenic protein in human non-small cell lung cancer. Biochem Biophys Res Commun 2014; 451(1): 119-25.
44. Corcoran DL, Pandit KV, Gordon B, Bhattacharjee A, Kaminski N, Benos PV. Features of mammalian microRNA promoters emerge from polymerase II chromatin immunoprecipitation data. PLoS One 2009; 4(4): e5279.
45. Hua X, Chen L, Wang J, Li J, Wingender E. Identifying cell-specific microRNA transcriptional start sites. Bioinformatics 2016; 32(16): 2403-10.
46. Ahn YH, Gibbons DL, Chakravarti D, et al. ZEB1 drives prometastatic actin cytoskeletal remodeling by downregulating miR-34a expression. J Clin Invest 2012; 122(9): 3170-83.
47. Zhang T, Guo L, Creighton CJ, et al. A genetic cell context-dependent role for ZEB1 in lung cancer. Nat Commun 2016; 7: 12231.
48. Guo L, Chen C, Shi M, et al. Stat3-coordinated Lin-28-let-7-HMGA2 and miR-200-ZEB1 circuits initiate and maintain on-costatin M-driven epithelial-mesenchymal transition. Oncogene 2013; 32(45): 5272-82.
49. Rice SJ, Lai SC, Wood LW, et al. MicroRNA-33a mediates the regulation of high mobility group AT-hook 2 gene (HMGA2) by thyroid transcription factor 1 (TTF-1/NKX2-1). J Biol Chem 2013; 288(23): 16348-60.
50. Sachdeva M, Dodd RD, Huang Z, et al. Epigenetic silencing of Kruppel like factor-3 increases expression of pro-metastatic miR-182. Cancer Lett 2015; 369(1): 202-11.
51. Dodd RD, Sachdeva M, Mito JK, et al. Myogenic transcription factors regulate pro-metastatic miR-182. Oncogene 2016; 35(14): 1868-75.
52. Antoniou A, Mastroyiannopoulos NP, Uney JB, Phylactou LA. miR-186 inhibits muscle cell differentiation through myogenin regulation. J Biol Chem 2014; 289(7): 3923-35.
53. Lin Y, Zhao J, Hu X, Wang L, Liang L, Chen W. Transcription factor CCAAT/enhancer binding protein alpha up-regulates microRNA let-7a-1 in lung cancer cells by direct binding. Cancer Cell Int 2016; 16: 17.
54. Duru N, Gernapudi R, Zhang Y, et al. NRF2/miR-140 signaling confers radioprotection to human lung fibroblasts. Cancer Lett 2015; 369(1): 184-91.
55. Singh A, Bodas M, Wakabayashi N, Bunz F, Biswal S. Gain of Nrf2 function in non-small-cell lung cancer cells confers radioresistance. Antioxid Redox Signal 2010; 13(11): 1627-37.
56. Donzelli S, Fontemaggi G, Fazi F, et al. MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function. Cell Death Differ 2012; 19(6): 1038-48.
57. Qu Y, Li WC, Hellem MR, et al. MiR-182 and miR-203 induce mesenchymal to epithelial transition and self-sufficiency of growth signals via repressing SNAI2 in prostate cells. Int J Cancer 2013; 133(3): 544-55.
58. Zhang Z, Zhang B, Li W, et al. Epigenetic silencing of miR-203 upregulates SNAI2 and contributes to the invasiveness of malignant breast cancer cells. Genes Cancer 2011; 2(8): 782-91.
59. Zhao G, Guo Y, Chen Z, et al. miR-203 functions as a tumor suppressor by inhibiting epithelial to mesenchymal transition in ovarian cancer. J Cancer Sci Ther 2015; 7(2): 34-43.
60. Ding X, Park SI, McCauley LK, Wang CY. Signaling between transforming growth factor β (TGF-β) and transcription factor SNAI2 represses expression of microRNA miR-203 to promote epithelial-mesenchymal transition and tumor metastasis. J Biol Chem 2013; 288(15): 10241-53.
61. Zu L, Xue Y, Wang J, et al. The feedback loop between miR-124 and TGF-β pathway plays a significant role in non-small cell lung cancer metastasis. Carcinogenesis 2016; 37(3): 333-43.
62. Zhang R, Zhang Y, Li H. miR-1244/myocyte enhancer factor 2D regulatory loop contributes to the growth of lung carcinoma. DNA Cell Biol 2015; 34(11): 692-700.
63. Davis-Dusenbery BN, Hata A. MicroRNA in cancer: The involvement of aberrant MicroRNA biogenesis regulatory pathways. Genes Cancer 2010; 1(11): 1100-14.
64. Shen J, Hung MC. Signaling-mediated regulation of MicroRNA processing. Cancer Res 2015; 75(5): 783-91.
65. Yao S. MicroRNA biogenesis and their functions in regulating stem cell potency and differentiation. Biol Proced Online 2016; 18: 8.
66. Ibberson D, Benes V, Muckenthaler MU, Castoldi M. RNA degradation compromises the reliability of microRNA expression profiling. BMC Biotechnol 2009; 9: 102.
67. Zhang Z, Qin YW, Brewer G, Jing Q. MicroRNA degradation and turnover: Regulating the regulators. Wiley Interdiscip Rev RNA 2012; 3(4): 593-600.
68. Zhang H, Lu Y, Chen E, et al. XRN2 promotes EMT and metastasis through regulating maturation of miR-10a. Oncogene 2017; 36(27): 3925-33.
69. Lønvik K, Sørbye SW, Nilsen MN, Paulssen RH. Prognostic value of the MicroRNA regulators Dicer and Drosha in non-small-cell lung cancer: co-expression of Drosha and miR-126 predicts poor survival. BMC Clin Pathol 2014; 14(1): 45.
70. Mayr F, Schütz A, Döge N, Heinemann U. The Lin28 cold-shock domain remodels pre-let-7 microRNA. Nucleic Acids Res 2012; 40(15): 7492-506.
71. Thornton JE, Chang HM, Piskounova E, Gregory RI. Lin28-mediated control of let-7 microRNA expression by alternative TUTases Zcchc11 (TUT4) and Zcchc6 (TUT7). RNA 2012; 18(10): 1875-85.
72. Fu X, Meng Z, Liang W, et al. miR-26a enhances miRNA biogenesis by targeting Lin28B and Zcchc11 to suppress tumor growth and metastasis. Oncogene 2014; 33(34): 4296-306.
73. Cha ST, Chen PS, Johansson G, et al. MicroRNA-519c suppresses hypoxia-inducible factor-1alpha expression and tumor angiogenesis. Cancer Res 2010; 70(7): 2675-85.
74. Jacob J, Favicchio R, Karimian N, et al. LMTK3 escapes tumour suppressor miRNAs via sequestration of DDX5. Cancer Lett 2016; 372(1): 137-46.
75. Sun C, Li S, Zhang F, et al. Long non-coding RNA NEAT1 promotes non-small cell lung cancer progression through regulation of miR-377-3p-E2F3 pathway. Oncotarget 2016; 7(32): 51784-814.
76. Troiani T, Napolitano S, Della Corte CM, et al. Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence. ESMO Open 2016; 1(5): e000088.
77. Pastorkova Z, Skarda J, Andel J. The role of microRNA in metastatic processes of non-small cell lung carcinoma. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2016; 160(3): 343-57.
78. Salgia R. MET in lung cancer: Biomarker selection based on scientific rationale. Mol Cancer Ther 2017; 16(4): 555-65.
79. Sun CC, Li SJ, Li DJ. Hsa-miR-134 suppresses non-small cell lung cancer (NSCLC) development through down-regulation of CCND1. Oncotarget 2016; 7(24): 35960-78.
80. Sun CC, Li SJ, Zhang F, et al. Hsa-miR-329 exerts tumor suppressor function through down-regulation of MET in non-small cell lung cancer. Oncotarget 2016; 7(16): 21510-26.
81. Shukuya T, Mori K, Amann JM, et al. Relationship between overall survival and response or progression-free survival in advanced non-small cell lung cancer patients treated with anti-pd-1/pd-l1 antibodies. J Thorac Oncol 2016; 11(11): 1927-39.
82. Zhang WC, Chin TM, Yang H, et al. Tumour-initiating cell-specific miR-1246 and miR-1290 expression converge to promote non-small cell lung cancer progression. Nat Commun 2016; 7: 11702.
83. Maione P, Sgambato A, Casaluce F, et al. The role of the antiangi-ogenetic ramucirumab in the treatment of advanced non small cell lung cancer. Curr Med Chem 2017; 24(1): 3-13.
84. Sun CC, Li SJ, Yuan ZP, Li DJ. MicroRNA-346 facilitates cell growth and metastasis, and suppresses cell apoptosis in human non-small cell lung cancer by regulation of XPC/ERK/Snail/E-cadherin pathway. Aging (Albany NY) 2016; 8(10): 2509-24.
85. Xi Y, Wang L, Sun C, Yang C, Zhang F, Li D. The novel miR-9501 inhibits cell proliferation, migration and activates apoptosis in non-small cell lung cancer. Med Oncol 2016; 33(11): 124.
86. Lara PN Jr, Lau DH, Gandara DR. Non-small-cell lung cancer progression after first-line chemotherapy. Curr Treat Options Oncol 2002; 3(1): 53-8.
87. Ansari J, Shackelford RE, El-Osta H. Epigenetics in non-small cell lung cancer: from basics to therapeutics. Transl Lung Cancer Res 2016; 5(2): 155-71.
88. Sun CC, Li SJ, Zhang F, et al. The novel miR-9600 suppresses tumor progression and promotes paclitaxel sensitivity in non-small-cell lung cancer through altering STAT3 expression. Mol Ther Nucleic Acids 2016; 5(11): e387.
89. Edmonds MD, Boyd KL, Moyo T, et al. MicroRNA-31 initiates lung tumorigenesis and promotes mutant KRAS-driven lung cancer. J Clin Invest 2016; 126(1): 349-64.
90. Coelho AL, et al. Angiogenesis in NSCLC: is vessel co-option the trunk that sustains the branches? Oncotarget 2016.
91. Hall RD, Le TM, Haggstrom DE, Gentzler RD. Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC). Transl Lung Cancer Res 2015; 4(5): 515-23.
92. Das M, Wakelee H. Angiogenesis and lung cancer: Ramucirumab prolongs survival in 2(nd)-line metastatic NSCLC. Transl Lung Cancer Res 2014; 3(6): 397-9.
93. Hsu YL, Hung JY, Chang WA, et al. Hypoxic lung cancer-secreted exosomal miR-23a increased angiogenesis and vascular permeability by targeting prolyl hydroxylase and tight junction protein ZO-1. Oncogene 2017; 36(34): 4929-42.
94. Dimitrova N, Gocheva V, Bhutkar A, et al. Stromal expression of miR-143/145 promotes neoangiogenesis in lung cancer development. Cancer Discov 2016; 6(2): 188-201.
95. Dong Z, Liang S, Hu J, Jin W, Zhan Q, Zhao K. Autophagy as a target for hematological malignancy therapy. Blood Rev 2016; 30(5): 369-80.
96. Chen K, Shi W. Autophagy regulates resistance of non-small cell lung cancer cells to paclitaxel. Tumour Biol 2016; 37(8): 10539-44.
97. You L, Wang Z, Li H, et al. The role of STAT3 in autophagy. Autophagy 2015; 11(5): 729-39.
98. Li S, Wang L, Hu Y, Sheng R. Autophagy regulators as potential cancer therapeutic agents: a review. Curr Top Med Chem 2015; 15(8): 720-44.
99. Rothschild SI, Gautschi O, Batliner J, Gugger M, Fey MF, Tschan MP. MicroRNA-106a targets autophagy and enhances sensitivity of lung cancer cells to Src inhibitors. Lung Cancer 2017; 107: 73-83.
100. Chatterjee A, Chattopadhyay D, Chakrabarti G. miR-17-5p downregulation contributes to paclitaxel resistance of lung cancer cells through altering beclin1 expression. PLoS One 2014; 9(4): e95716.
101. Wei J, Ma Z, Li Y, et al. miR-143 inhibits cell proliferation by targeting autophagy-related 2B in non-small cell lung cancer H1299 cells. Mol Med Rep 2015; 11(1): 571-6.
102. Sha HH, Wang DD, Chen D, et al. MiR-138: A promising therapeutic target for cancer. Tumour Biol 2017; 39(4): 1010428317697575.
103. Han LP, Fu T, Lin Y, Miao JL, Jiang QF. MicroRNA-138 negatively regulates non-small cell lung cancer cells through the interaction with cyclin D3. Tumour Biol 2016; 37(1): 291-8.
104. Wang Q, Zhong M, Liu W, Li J, Huang J, Zheng L. Alterations of microRNAs in cisplatin-resistant human non-small cell lung cancer cells (A549/DDP). Exp Lung Res 2011; 37(7): 427-34.
105. Jin Z, Guan L, Song Y, Xiang GM, Chen SX, Gao B. MicroRNA-138 regulates chemoresistance in human non-small cell lung cancer via epithelial mesenchymal transition. Eur Rev Med Pharmacol Sci 2016; 20(6): 1080-6.
106. Li J, Wang Q, Wen R, et al. MiR-138 inhibits cell proliferation and reverses epithelial-mesenchymal transition in non-small cell lung cancer cells by targeting GIT1 and SEMA4C. J Cell Mol Med 2015; 19(12): 2793-805.
107. Yang T, Li H, Thakur A, et al. FOXP4 modulates tumor growth and independently associates with miR-138 in non-small cell lung cancer cells. Tumour Biol 2015; 36(10): 8185-91.
108. Zhang H, Zhang H, Zhao M, et al. MiR-138 inhibits tumor growth through repression of EZH2 in non-small cell lung cancer. Cell Physiol Biochem 2013; 31(1): 56-65.
109. Han L, Zhang G, Zhang N, et al. Prognostic potential of microRNA-138 and its target mRNA PDK1 in sera for patients with non-small cell lung cancer. Med Oncol 2014; 31(9): 129.
110. Xiao L, Zhou H, Li XP, et al. MicroRNA-138 acts as a tumor suppressor in non small cell lung cancer via targeting YAP1. Oncotarget 2016; 7(26): 40038-46.
111. Gao Y, Fan X, Li W, Ping W, Deng Y, Fu X. miR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124. Biochem Biophys Res Commun 2014; 446(1): 179-86.
112. Yang G, Zhang W, Yu C, Ren J, An Z. MicroRNA let-7: Regulation, single nucleotide polymorphism, and therapy in lung cancer. J Cancer Res Ther 2015; 11(Suppl. 1): C1-6.
113. Wang X, Cao L, Wang Y, Wang X, Liu N, You Y. Regulation of let-7 and its target oncogenes (Review). Oncol Lett 2012; 3(5): 955-60.
114. Jérôme T, Laurie P, Louis B, Pierre C. Enjoy the silence: The story of let-7 MicroRNA and cancer. Curr Genomics 2007; 8(4): 229-33.
115. Zhang W, Winder T, Ning Y, et al. A let-7 microRNA-binding site polymorphism in 3′-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy. Ann Oncol 2011; 22(1): 104-9.
116. Zhao B, Han H, Chen J, et al. MicroRNA let-7c inhibits migration and invasion of human non-small cell lung cancer by targeting ITGB3 and MAP4K3. Cancer Lett 2014; 342(1): 43-51.
117. Alam M, Ahmad R, Rajabi H, Kufe D. MUC1-C Induces the LIN28B→LET-7→HMGA2 Axis to Regulate Self-Renewal in NSCLC. Mol Cancer Res 2015; 13(3): 449-60.
118. Haselmann V, Kurz A, Bertsch U, et al. Nuclear death receptor TRAIL-R2 inhibits maturation of let-7 and promotes proliferation of pancreatic and other tumor cells. Gastroenterology 2014; 146(1): 278-90.
119. Shen H, Liu J, Wang R, et al. Fulvestrant increases gefitinib sensitivity in non-small cell lung cancer cells by upregulating let-7c expression. Biomed Pharmacother 2014; 68(3): 307-13.
120. Zhan M, Qu Q, Wang G, et al. Let-7c inhibits NSCLC cell proliferation by targeting HOXA1. Asian Pac J Cancer Prev 2013; 14(1): 387-92.
121. Zhan M, Qu Q, Wang G, Zhou H. Let-7c sensitizes acquired cisplatin-resistant A549 cells by targeting ABCC2 and Bcl-XL. Phar-mazie 2013; 68(12): 955-61.
122. Lu L, Qi H, Luo F, et al. Feedback circuitry via let-7c between lncRNA CCAT1 and c-Myc is involved in cigarette smoke extract-induced malignant transformation of HBE cells. Oncotarget 2017; 8(12): 19285-97.
123. Ren F, Zhang X, Liang H, et al. Prognostic significance of MiR-34a in solid tumors: A systemic review and meta-analysis with 4030 patients. Int J Clin Exp Med 2015; 8(10): 17377-91.
124. Farooqi AA, Fayyaz S, Shatynska-Mytsyk I, et al. Is miR-34a a well-equipped swordsman to conquer temple of molecular oncology? Chem Biol Drug Des 2016; 87(3): 321-34.
125. Duan W, Xu Y, Dong Y, Cao L, Tong J, Zhou X. Ectopic expression of miR-34a enhances radiosensitivity of non-small cell lung cancer cells, partly by suppressing the LyGDI signaling pathway. J Radiat Res (Tokyo) 2013; 54(4): 611-9.
126. Ji X, Wang Z, Geamanu A, Goja A, Sarkar FH, Gupta SV. Delta-tocotrienol suppresses Notch-1 pathway by upregulating miR-34a in nonsmall cell lung cancer cells. Int J Cancer 2012; 131(11): 2668-77.
127. Ma ZL, Hou PP, Li YL, et al. MicroRNA-34a inhibits the proliferation and promotes the apoptosis of non-small cell lung cancer H1299 cell line by targeting TGFβR2. Tumour Biol 2015; 36(4): 2481-90.
128. Lee JH, Voortman J, Dingemans AM, et al. MicroRNA expression and clinical outcome of small cell lung cancer. PLoS One 2011; 6(6): e21300.
129. Shen H, Zhu F, Liu J, et al. Alteration in Mir-21/PTEN expression modulates gefitinib resistance in non-small cell lung cancer. PLoS One 2014; 9(7): e103305.
130. Zhang J, Zhang C, Hu L, et al. Abnormal expression of miR-21 and miR-95 in cancer stem-like cells is associated with radioresistance of lung cancer. Cancer Invest 2015; 33(5): 165-71.
131. Wu ZH, Tao ZH, Zhang J, et al. MiRNA-21 induces epithelial to mesenchymal transition and gemcitabine resistance via the PTEN/AKT pathway in breast cancer. Tumour Biol 2016; 37(6): 7245-54.
132. Liu ZL, Wang H, Liu J, Wang ZX. MicroRNA-21 (miR-21) expression promotes growth, metastasis, and chemo- or radioresistance in non-small cell lung cancer cells by targeting PTEN. Mol Cell Biochem 2013; 372(1-2): 35-45.
133. Zhang JG, Wang JJ, Zhao F, Liu Q, Jiang K, Yang GH. MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). Clin Chim Acta 2010; 411(11-12): 846-52.
134. Yang Y, Meng H, Peng Q, et al. Downregulation of microRNA-21 expression restrains non-small cell lung cancer cell proliferation and migration through upregulation of programmed cell death 4. Cancer Gene Ther 2015; 22(1): 23-9.
135. Xu LF, Wu ZP, Chen Y, Zhu QS, Hamidi S, Navab R. MicroRNA-21 (miR-21) regulates cellular proliferation, invasion, migration, and apoptosis by targeting PTEN, RECK and Bcl-2 in lung squamous carcinoma, Gejiu City, China. PLoS One 2014; 9(8): e103698.
136. Wu T, Chen W, Kong D, et al. miR-25 targets the modulator of apoptosis 1 gene in lung cancer. Carcinogenesis 2015; 36(8): 925-35.
137. Chen Z, Wu Y, Meng Q, Xia Z. Elevated microRNA-25 inhibits cell apoptosis in lung cancer by targeting RGS3. In Vitro Cell Dev Biol Anim 2016; 52(1): 62-7.
138. Xiang J, Hang JB, Che JM, Li HC. MiR-25 is up-regulated in non-small cell lung cancer and promotes cell proliferation and motility by targeting FBXW7. Int J Clin Exp Pathol 2015; 8(8): 9147-53.
139. Yang T, Chen T, Li Y, et al. Downregulation of miR-25 modulates non-small cell lung cancer cells by targeting CDC42. Tumour Biol 2015; 36(3): 1903-11.
140. Lo Sardo F, Forcato M, Sacconi A, et al. MCM7 and its hosted miR-25, 93 and 106b cluster elicit YAP/TAZ oncogenic activity in lung cancer. Carcinogenesis 2017; 38(1): 64-75.
141. Liao BC, Lin CC, Yang JC. Novel EGFR inhibitors in non-small cell lung cancer: Current status of afatinib. Curr Oncol Rep 2017; 19(1): 4.
142. Xiao J, Hu CP, He BX, et al. PTEN expression is a prognostic marker for patients with non-small cell lung cancer: a systematic review and meta-analysis of the literature. Oncotarget 2016; 7(36):57832-40.
143. Pérez-Ramírez C, Cañadas-Garre M, Molina MÁ, Faus-Dáder MJ, Calleja-Hernández MÁ. PTEN and PI3K/AKT in non-small-cell lung cancer. Pharmacogenomics 2015; 16(16): 1843-62.
144. Thomadaki H, Scorilas A. BCL2 family of apoptosis-related genes: functions and clinical implications in cancer. Crit Rev Clin Lab Sci 2006; 43(1): 1-67.
145. Zhang P, Sun Y, Ma L. ZEB1: at the crossroads of epithelial-mesenchymal transition, metastasis and therapy resistance. Cell Cycle 2015; 14(4): 481-7.
146. Hill L, Browne G, Tulchinsky E. ZEB/miR-200 feedback loop: at the crossroads of signal transduction in cancer. Int J Cancer 2013; 132(4): 745-54.
147. Nurwidya F, Andarini S, Takahashi F, Syahruddin E, Takahashi K. Implications of insulin-like growth factor 1 receptor activation in lung cancer. Malays J Med Sci 2016; 23(3): 9-21.
148. Georgakilas AG, Martin OA, Bonner WM. p21: A Two-Faced Genome Guardian. Trends Mol Med 2017; 23(4): 310-9.
149. Gartel AL. p21(WAF1/CIP1) and cancer: A shifting paradigm? Biofactors 2009; 35(2): 161-4.
150. Jackstadt R, Hermeking H. MicroRNAs as regulators and mediators of c-MYC function. Biochim Biophys Acta 2015; 1849(5): 544-53.
151. Kuzyk A, Mai S. c-MYC-induced genomic instability. Cold Spring Harb Perspect Med 2014; 4(4): a014373.
152. Wang L, Yao J, Sun H, et al. MicroRNA-101 suppresses progression of lung cancer through the PTEN/AKT signaling pathway by targeting DNA methyltransferase 3A. Oncol Lett 2017; 13(1): 329-38.
153. Song L, Li D, Gu Y, et al. MicroRNA-126 Targeting PIK3R2 inhibits NSCLC A549 cell proliferation, migration, and invasion by regulation of PTEN/PI3K/AKT pathway. Clin Lung Cancer 2016; 17(5): e65-75.
154. Li J, Wang H, Ke H, Ni S. MiR-129 regulates MMP9 to control metastasis of non-small cell lung cancer. Tumour Biol 2015; 36(8): 5785-90.
155. Zhang Y, An J, Lv W, Lou T, Liu Y, Kang W. miRNA-129-5p suppresses cell proliferation and invasion in lung cancer by targeting microspherule protein 1, E-cadherin and vimentin. Oncol Lett 2016; 12(6): 5163-9.
156. Liu G, Li YI, Gao X. Overexpression of microRNA-133b sensitizes non-small cell lung cancer cells to irradiation through the inhibition of glycolysis. Oncol Lett 2016; 11(4): 2903-8.
157. Yang X, Lei P, Huang Y, Zhang Z, Zhang Y. MicroRNA-133b inhibits the migration and invasion of non small cell lung cancer cells via targeting FSCN1. Oncol Lett 2016; 12(5): 3619-25.
158. Qin Q, Wei F, Zhang J, Li B. miR-134 suppresses the migration and invasion of non-small cell lung cancer by targeting ITGB1. Oncol Rep 2017; 37(2): 823-30.
159. Zhang X, Zhang X, Yu B, Hu R, Hao L. Oncogene LSD1 is epigenetically suppressed by miR-137 overexpression in human non-small cell lung cancer. Biochimie 2017; 137: 12-9.
160. Xu W, Hang M, Yuan CY, Wu FL, Chen SB, Xue K. MicroRNA-139-5p inhibits cell proliferation and invasion by targeting insulin-like growth factor 1 receptor in human non-small cell lung cancer. Int J Clin Exp Pathol 2015; 8(4): 3864-70.
161. Xiao P, Liu WL. MiR-142-3p functions as a potential tumor suppressor directly targeting HMGB1 in non-small-cell lung carcinoma. Int J Clin Exp Pathol 2015; 8(9): 10800-7.
162. Zhang HB, Sun LC, Ling L, Cong LH, Lian R. miR-143 suppresses the proliferation of NSCLC cells by inhibiting the epidermal growth factor receptor. Exp Ther Med 2016; 12(3): 1795-802.
163. He M, Xue Y. MicroRNA-148a suppresses proliferation and invasion potential of non-small cell lung carcinomas via regulation of STAT3. Onco Targets Ther 2017; 10: 1353-61.
164. Xu W, Jiang K, Shen M, Chen Y, Huang HY. Jumonji domain containing 2A predicts prognosis and regulates cell growth in lung cancer depending on miR-150. Oncol Rep 2016; 35(1): 352-8.
165. Zhang YJ, Liu XC, Du J, Zhang YJ. MiR-152 regulates metastases of non-small cell lung cancer cells by targeting neuropilin-1. Int J Clin Exp Pathol 2015; 8(11): 14235-40.
166. Hou L, Chen J, Zheng Y, Wu C. Critical role of miR-155/FoxO1/ROS axis in the regulation of non-small cell lung carcinomas. Tumour Biol 2016; 37(4): 5185-92.
167. Lv X, Yao L, Zhang J, Han P, Li C. Inhibition of microRNA-155 sensitizes lung cancer cells to irradiation via suppression of HK2-modulated glucose metabolism. Mol Med Rep 2016; 14(2): 1332-8.
168. Yang T, Thakur A, Chen T, et al. MicroRNA-15a induces cell apoptosis and inhibits metastasis by targeting BCL2L2 in non-small cell lung cancer. Tumour Biol 2015; 36(6): 4357-65.
169. Liang C, Zhang X, Wang HM, et al. MicroRNA-18a-5p functions as an oncogene by directly targeting IRF2 in lung cancer. Cell Death Dis 2017; 8(5): e2764.
170. Chatterjee A, Chattopadhyay D, Chakrabarti G. MiR-16 targets Bcl-2 in paclitaxel-resistant lung cancer cells and overexpression of miR-16 along with miR-17 causes unprecedented sensitivity by simultaneously modulating autophagy and apoptosis. Cell Signal 2015; 27(2): 189-203.
171. Liu Y, Hu X, Xia D, Zhang S. MicroRNA-181b is downregulated in non-small cell lung cancer and inhibits cell motility by directly targeting HMGB1. Oncol Lett 2016; 12(5): 4181-6.
172. Lin TC, Lin PL, Cheng YW, et al. MicroRNA-184 deregulated by the MicroRNA-21 promotes tumor malignancy and poor outcomes in non-small cell lung cancer via targeting CDC25A and c-Myc. Ann Surg Oncol 2015; 22(Suppl. 3): S1532-9.
173. Pei K, Zhu JJ, Wang CE, Xie QL, Guo JY. MicroRNA-185-5p modulates chemosensitivity of human non-small cell lung cancer to cisplatin via targeting ABCC1. Eur Rev Med Pharmacol Sci 2016; 20(22): 4697-704.
174. Huang T, She K, Peng G, et al. MicroRNA-186 suppresses cell proliferation and metastasis through targeting MAP3K2 in non-small cell lung cancer. Int J Oncol 2016; 49(4): 1437-44.
175. Peng J, Liu HZ, Zhong J, et al. MicroRNA-187 is an independent prognostic factor in lung cancer and promotes lung cancer cell invasion via targeting of PTRF. Oncol Rep 2016; 36(5): 2609-18.
176. Dou C, Liu Z, Xu M, et al. miR-187-3p inhibits the metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by targeting S100A4. Cancer Lett 2016; 381(2): 380-90.
177. Mi J, Zou Y, Lin X, et al. Dysregulation of the miR-194-CUL4B negative feedback loop drives tumorigenesis in non-small-cell lung carcinoma. Mol Oncol 2017; 11(3): 305-19.
178. Guo H, Li W, Zheng T, Liu Z. MiR-195 targets HDGF to inhibit proliferation and invasion of NSCLC cells. Tumour Biol 2014; 35(9): 8861-6.
179. Yu SL, Lee DC, Sohn HA, et al. Homeobox A9 directly targeted by miR-196b regulates aggressiveness through nuclear Factor-kappa B activity in non-small cell lung cancer cells. Mol Carcinog 2016; 55(12): 1915-26.
180. Zhou G, Zhang F, Guo Y, et al. miR-200c enhances sensitivity of drug-resistant non-small cell lung cancer to gefitinib by suppression of PI3K/Akt signaling pathway and inhibites cell migration via targeting ZEB1. Biomed Pharmacother 2017; 85: 113-9.
181. Wang P, Lv HY, Zhou DM, Zhang EN. miR-204 suppresses non-small-cell lung carcinoma (NSCLC) invasion and migration by targeting JAK2. Genet Mol Res 2016; 15(2): doi: 10.4238/gmr.15026415.
182. Zhang S, Gao L, Thakur A, et al. miRNA-204 suppresses human non-small cell lung cancer by targeting ATF2. Tumour Biol 2016; 37(8): 11177-86.
183. Zeng Y, Zhu J, Shen D, et al. Repression of Smad4 by miR-205 moderates TGF-β-induced epithelial-mesenchymal transition in A549 cell lines. Int J Oncol 2016; 49(2): 700-8.
184. Babu KR, Muckenthaler MU. miR-20a regulates expression of the iron exporter ferroportin in lung cancer. J Mol Med (Berl) 2016; 94(3): 347-59.
185. Lu L, Zhang X, Zhang B, Wu J, Zhang X. Synaptic acetylcho-linesterase targeted by microRNA-212 functions as a tumor suppressor in non-small cell lung cancer. Int J Biochem Cell Biol 2013; 45(11): 2530-40.
186. Wang RT, Xu M, Xu CX, Song ZG, Jin H. Decreased expression of miR216a contributes to non-small-cell lung cancer progression. Clin Cancer Res 2014; 20(17): 4705-16.
187. Xie J, Yu F, Li D, Zhu X, Zhang X, Lv Z. MicroRNA-218 regulates cisplatin (DPP) chemosensitivity in non-small cell lung cancer by targeting RUNX2. Tumour Biol 2016; 37(1): 1197-204.
188. Cui R, Kim T, Fassan M, et al. MicroRNA-224 is implicated in lung cancer pathogenesis through targeting caspase-3 and caspase-7. Oncotarget 2015; 6(26): 21802-15.
189. Cao M, Li Y, Lu H, et al. MiR-23a-mediated migration/invasion is rescued by its target, IRS-1, in non-small cell lung cancer cells. J Cancer Res Clin Oncol 2014; 140(10): 1661-70.
190. Li D, Wei Y, Wang D, Gao H, Liu K. MicroRNA-26b suppresses the metastasis of non-small cell lung cancer by targeting MIEN1 via NF-κB/MMP-9/VEGF pathways. Biochem Biophys Res Commun 2016; 472(3): 465-70.
191. Zhou H, Liu Y, Xiao L, Hu Z, Xia K. Overexpression of Mi-croRNA-27b Inhibits Proliferation, Migration, and Invasion via Suppression of MET Expression. Oncol Res 2017; 25(1): 147-54.
192. Pandey M, Sultana S, Gupta KP. Involvement of epigenetics and microRNA-29b in the urethane induced inception and establishment of mouse lung tumors. Exp Mol Pathol 2014; 96(1): 61-70.
193. Xu C, Li S, Chen T, et al. miR-296-5p suppresses cell viability by directly targeting PLK1 in non-small cell lung cancer. Oncol Rep 2016; 35(1): 497-503.
194. Luo W, Lin Y, Meng S, Guo Y, Zhang J, Zhang W. miRNA-296-3p modulates chemosensitivity of lung cancer cells by targeting CX3CR1. Am J Transl Res 2016; 8(4): 1848-56.
195. Pastuszak-Lewandoska D, Kordiak J, Czarnecka KH, et al. Expression analysis of three miRNAs, miR-26a, miR-29b and miR-519d, in relation to MMP-2 expression level in non-small cell lung cancer patients: A pilot study. Med Oncol 2016; 33(8): 96.
196. Ma ZL, Zhang BJ, Wang DT, et al. Tanshinones suppress AURKA through up-regulation of miR-32 expression in non-small cell lung cancer. Oncotarget 2015; 6(24): 20111-20.
197. Zhu D, Chen H, Yang X, et al. miR-32 functions as a tumor suppressor and directly targets SOX9 in human non-small cell lung cancer. Onco Targets Ther 2015; 8: 1773-83.
198. Zhang P, Shao G, Lin X, Liu Y, Yang Z. MiR-338-3p inhibits the growth and invasion of non-small cell lung cancer cells by targeting IRS2. Am J Cancer Res 2017; 7(1): 53-63.
199. Tai MC, Kajino T, Nakatochi M, et al. miR-342-3p regulates MYC transcriptional activity via direct repression of E2F1 in human lung cancer. Carcinogenesis 2015; 36(12): 1464-73.
200. Cortez MA, Ivan C, Valdecanas D, et al. PDL1 Regulation by p53 via miR-34. J Natl Cancer Inst 2015; 108(1): djv303.
201. Ma Y, Bao C, Kong R, et al. MicroRNA-361-5p suppresses cancer progression by targeting signal transducer and activator of transcription 6 in non-small cell lung cancer. Mol Med Rep 2015; 12(5): 7367-73.
202. Zhang X, Ke X, Pu Q, et al. MicroRNA-410 acts as oncogene in NSCLC through downregulating SLC34A2 via activating Wnt/β-catenin pathway. Oncotarget 2016; 7(12): 14569-85.
203. Xiao P, Liu W, Zhou H. miR-429 promotes the proliferation of non-small cell lung cancer cells via targeting DLC-1. Oncol Lett 2016; 12(3): 2163-8.
204. Zhang YL, et al. The lncRNA XIST exhibits oncogenic properties via regulation of miR-449a and Bcl-2 in human non-small cell lung cancerThis article has been corrected since Advanced Online Publication, and an erratum is also printed in this issue. Acta Pharmacol Sin 2017; 38(3): 371-81.
205. Cheng D, Xu Y, Sun C, He Z. MicroRNA-451 sensitizes lung cancer cells to cisplatin through regulation of Mcl-1. Mol Cell Biochem 2016; 423(1-2): 85-91.
206. Borzi C, Calzolari L, Centonze G, Milione M, Sozzi G, Fortunato O. mir-660-p53-mir-486 Network: A New Key Regulatory Pathway in Lung Tumorigenesis. Int J Mol Sci 2017; 18(1): E222.
207. Song L, Li Y, Li W, Wu S, Li Z. miR-495 enhances the sensitivity of non-small cell lung cancer cells to platinum by modulation of copper-transporting P-type adenosine triphosphatase A (ATP7A). J Cell Biochem 2014; 115(7): 1234-42.
208. Gu A, Lu J, Wang W, Shi C, Han B, Yao M. Role of miR-497 in VEGF-A-mediated cancer cell growth and invasion in non-small cell lung cancer. Int J Biochem Cell Biol 2016; 70: 118-25.
209. Liu Y, Miao L, Ni R, et al. microRNA-520a-3p inhibits proliferation and cancer stem cell phenotype by targeting HOXD8 in non-small cell lung cancer. Oncol Rep 2016; 36(6): 3529-35.
210. Zhang Y, Xu X, Zhang M, et al. MicroRNA-663a is downregulated in non-small cell lung cancer and inhibits proliferation and invasion by targeting JunD. BMC Cancer 2016; 16: 315.
211. Zeng J, Cai S. Breviscapine suppresses the growth of non-small cell lung cancer by enhancing microRNA-7 expression. J Biosci 2017; 42(1): 121-9.
212. Guo GC, Wang JX, Han ML, Zhang LP, Li L. microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression. Cell Oncol (Dordr) 2017; 40(2): 157-66.
213. Han L, Wang W, Ding W, Zhang L. MiR-9 is involved in TGF-β1-induced lung cancer cell invasion and adhesion by targeting SOX7. J Cell Mol Med 2017; 21(9): 2000-8.
214. Xu G, Shao G, Pan Q, et al. MicroRNA-9 regulates non-small cell lung cancer cell invasion and migration by targeting eukaryotic translation initiation factor 5A2. Am J Transl Res 2017; 9(2): 478-88.
215. Lei L, Huang Y, Gong W. Inhibition of miR-92b suppresses nonsmall cell lung cancer cells growth and motility by targeting RECK. Mol Cell Biochem 2014; 387(1-2): 171-6.
216. Li J, Li P, Chen T, et al. Expression of microRNA-96 and its potential functions by targeting FOXO3 in non-small cell lung cancer. Tumour Biol 2015; 36(2): 685-92.
217. Liu W, et al. MicroRNA-98 plays a suppressive role in non-small cell lung cancer through inhibition of SALL4 protein expression. Oncol Res 2016.
218. Chen C, Zhao Z, Liu Y, Mu D. microRNA-99a is downregulated and promotes proliferation, migration and invasion in non-small cell lung cancer A549 and H1299 cells. Oncol Lett 2015; 9(3): 1128-34.
219. Yu SH, Zhang CL, Dong FS, Zhang YM. miR-99a suppresses the metastasis of human non-small cell lung cancer cells by targeting AKT1 signaling pathway. J Cell Biochem 2015; 116(2): 268-76.